Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven recurrent or refractory pediatric solid tumor
• Bone marrow metastases allowed
• PATIENT CHARACTERISTICS:
• Age:
• 1 to 30
• Performance status:
• 0-2
• Life expectancy:
• At least 2 months
• Hematopoietic:
• Absolute neutrophil count at least 1,000/mm3
• Platelet count at least 100,000/mm3 (transfusion independent)
• Hemoglobin at least 10 g/dL (RBC transfusion allowed)
• Hepatic:
• Bilirubin no greater than 1.5 times normal
• SGOT no greater than 2.5 times normal
• Renal:
• Adequate renal function as defined by one of the following:
• * GFR by creatinine clearance
• * Radioisotope GFR
• * Iothalamate at least 70 mL/min
• Cardiovascular:
• Adequate cardiac function as defined by one of the following:
• * Ejection fraction at least 55% by MUGA
• * Fractional shortening at least 28% by echocardiogram
• Neurologic:
• Adequate CNS function as defined by:
• * Seizure disorder, if present, controlled by anticonvulsants
• * CNS toxicity no greater than grade 2
• Other:
• No uncontrolled infections
• Not pregnant or nursing
• No allergy to platinum compounds
• No history of allergy to etoposide (unless mobilization phase not required)
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Recovered from prior immunotherapy
• At least 1 week since prior cytokines
• At least 3 months since prior bone marrow or peripheral blood stem cell transplantation
• No concurrent immunomodulator
• No concurrent cytokines
• Chemotherapy:
• At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered
• No prior thiotepa
• No other concurrent chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Recovered from prior radiotherapy
• At least 6 months since prior total body irradiation conditioning
• No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow
• Surgery:
• Not specified